Methods: Thirty patients diagnosed as coronary artery disease undergoing diagnostic coronary angiography were enrolled in the study. Subjects with chronic obstructive pulmonary disease, asthma, allergic bronchitis, myocardial infarction and documented systolic dysfunction by transthoracic echocardiography were excluded. The respiratory functions of the patients before and immediately after the coronary angiography were measured and arterial blood gas analyses were performed. The subjects were divided into two groups according to results of angiography as having coronary artery disease (Group 1) and without significant coronary artery disease (Group 2). The angiography procedures were performed by a single, experienced angiographer. Left Ventriculography was not performed on any patient
Results: The results gathered before and after angiography procedure were compared. Forced expiratory volume in the first second (FEV1), maximum mid-expiratory flow rate, (MMFR) 25-75, arterial oxygen pressure (PaO2) and bicarbonate (HCO3) were significantly reduced ( p < 0.01), where as forced vital capacity (FVC), pH, oxygen saturation and arterial carbondioxide pressure were not changed. The comparison between two groups resulted that FEV1 and PaO2 were significantly decreased after angiography in Group 1.
Conclusions: Diagnostic coronary angiography using iohexol decreases ventilatory functions in a small but significant extent in patients without any overt pulmonary disease. Therefore they should be used cautiously in patients with chronic lung disease.
The contrast agent studied was iohexol; a non-ionic monomeric media with a molecular weight of 821.14 and iodine content of 46%. The concentration used for the study was commercially available formulation (Omnipaque-350) containing 350 mg/mL of iodine with an osmolality of 844 mOsm/kg of water. The angiography procedures were performed through the radial artery route by a single, experienced angiographer with 5 F Judkins diagnostic catheters with catheter exchange over a 0.035-inch guide wire. Totally five multiple angled views of the left and right coronary arteries were recorded in all patients by hand injection. Mean procedural duration was 19.1 ± 4.6 min and mean contrast media used was 86.8 ± 37.94 millilitres. No patients were performed ventriculography.
Statistical Evaluation
Statistical analysis was performed using Statistics Package for Social Sciences (SPSS 10.0 for windows) software. The variables gathered before and after angiography were compared using paired t-test. Also the subjects divided into two groups according to results of angiography as having coronary artery disease (Group 1) and without significant coronary artery disease (Group 2). Quantitative variables between groups were given as mean ± standard deviation. Quantitative values between groups were compared by Student t test and qualitative values were compared by chi-square test. A pvalue of < = 0.05 was considered to be significant.
When the patients were grouped according to significant coronary artery disease presence; FEV1 and PaO2 were significantly lower in the patients with coronary artery disease (Table 2). Absence of coronary artery disease did not alter the adverse effects documented with ventilatory tests.
Table 2: The comparison of results of pulmonary tests in different groups.
The efficacy and safety of different contrast agents had been investigated in human subjects by coronary and respiratory artery injection. Kumazaki [3] evaluated the first study in man in which the change in pulmonary arterial pressure was recorded immediately after the rapid injections of hypertonic contrast media (diatroziate and ioxaglate) into the pulmonary artery. Tajima and associates [5] compared diatrizoate and iohexol with a study, concluding diatrozoate produced a significant rise and continuous elevation in both systolic and diastolic pulmonary arterial pressure, where as iohexol caused only a transient mild elevation.
The effects of different contrast agents on ventilatory functions were also studied before. Wilson and associates [5] compared ionic contrast agent sodium iothalamate with non-ionic dimmer iopamidol. The patients in both groups showed a significant reduction in FEV1 and FVC after diagnostic urography performed with the mentioned agents, and there was no superiority between iopamidol and iothalamate when lowering adverse effects were concerned.
The reductions in FEV1 are possibly due to the asymptomatic bronchospasm. The underlying mechanism may involve a direct effect on the bronchi, the release of the bronchospastic mediators from mast cells and platelets, cholinesterase inhibition, vagal reflex and complement activation [6]. Laude and associates [7] concluded that the decrease in PaO2 might reflect the decrease in alveolar perfusion. In their study with Wister rats, all diatrizoate, ioxaglate and iopromide caused significant falls in PaO2. But, these changes were insufficient to trigger a ventilatory response. The authors speculated an inhibitory action on respiratory centres in the brain and carotid body. Cipolla and associates [8] investigated the effects of contrast media on pulmonary airway resistance and the mechanism underlying potential bronchoconstrictor effects in guinea pigs. They concluded that there was no apparent relationship between the size of the increase in airway resistance and pharmaceutical formulation. At the time being, the mechanism of bronchospasm after contrast media injection in circulation is still unclear.
The present data compare the ventilatory effects in human subjects after coronary angiography. The contrast media used was iohexol, accepted as one of the standard contrast agents in cardiologic procedures and had been in use nearly for two decades. Although this agent is superior to former ionic contrast media in case of adverse effects, it is not completely perfect. The relative rarity of major reactions with iohexol should not lead the decision that they are totally safe and negative effects on ventilatory functions due to possible asymptomatic bronchospasm, should not be ignored.
1) Dawson P. Cardiovascular effects of contrast agents. Am J Cardiol 1989;64:2-9.
2) Higgins CB. Cardiotolerance of iohexol. Survey of experimental evidence. Invest Radiol 1985;20:2-9.
3) Wilson ARM, Davies P. Ventilatory function during urography: A comparison of iopamidol and sodium iothalamate. Clin Radiol 1988;39:490-3.
4) Kumazaki T. Ioxyglate versus diatrazoate in selective pulmonary angiographyand cardiovascular responses. Acta Radiol 1985;26:635-40.
5) Tajima H, Kumazaki T, Tajima N, Ebata K. Effect of iohexol and diatrizoate on pulmonary arterial pressure following pulmonary angiography. Acta Radiol, 1988;29:487-90.
6) Dawson P, Pitfield J, Britain J. Contrast media and bronchospasm: A study with iopamidol. Clin Radiol 1983;34:227-30.